Sol-Gel Technologies (NASDAQ:SLGL) Upgraded by Wall Street Zen to Buy Rating

Key Points

• Sol-Gel Technologies has been upgraded to a "buy" rating by Wall Street Zen, indicating increased investor confidence in the company's prospects.
• The company's stock price increased by 2.3%, reflecting positive market reactions following the upgrade.
• In its latest earnings report, Sol-Gel Technologies posted an impressive $4.17 EPS, significantly beating analysts' expectations of a loss.

Sol-Gel Technologies (NASDAQ:SLGL - Get Free Report) was upgraded by equities researchers at Wall Street Zen to a "buy" rating in a report issued on Saturday.

Sol-Gel Technologies Stock Up 7.9%

Shares of Sol-Gel Technologies stock traded up $1.93 during trading hours on Friday, reaching $26.28. 49,825 shares of the company's stock were exchanged, compared to its average volume of 30,468. Sol-Gel Technologies has a 1 year low of $4.01 and a 1 year high of $30.00. The company has a market capitalization of $73.33 million, a P/E ratio of -21.37 and a beta of 1.26. The business has a fifty day moving average of $17.41 and a two-hundred day moving average of $10.31.

Sol-Gel Technologies (NASDAQ:SLGL - Get Free Report) last released its earnings results on Friday, August 15th. The company reported $4.17 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.67) by $4.84. Sol-Gel Technologies had a negative net margin of 14.25% and a negative return on equity of 11.80%. The business had revenue of $17.26 million during the quarter, compared to analyst estimates of $2.86 million. As a group, research analysts predict that Sol-Gel Technologies will post -0.28 EPS for the current year.

About Sol-Gel Technologies

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc, develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.